PPT-Latest Clinical Research in Migraine Prevention Therapy

This program will include a discussion of data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal Introduction to CGRP as a Treatment Target in Migraine Prevention. The expanding border is often described as “shimmering” or associated with “zig-zag” lines, “heat waves,” or “sparklers.” While most frequently followed by a Remedy: Acupuncture and Herbs. Time: 1-2 weeks the Migraine is away.. Cost: $380CAD. Success Rate: >85%.. Offer Herbs for prevention. . Migraine. A headache with throbbing pain that is usually worse on one side of the head. . Gaston. Migraines. Chief Complaint. : “ I’ve . been having really bad headaches that won’t go away.”. HPI. : Patient . L.R. . . is a . 28 . year old Caucasian . female . that presents to the clinic with complaints . 10-12% of general population are active migraineurs (at least one attack in last year).. > 5% have at least 18 migraine days per year.. Female: Male ratio 3:1 – this ratio rises from menarche, peaks at 42, then declines.. AMG334 /Aimovig™ . Goadsby. PJ, Reuter U, . Hallström. Y, . Broessner. G, Bonner JH, Zhang F, . Sapra. S, Picard H, . Mikol. DD, Lenz RA. N . Engl. J Med 2017; 377:2123-2132 November 30, 2017. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Introduction to CGRP as a Treatment Target in Migraine Prevention. Migraine Headaches:   Did You Know? By Tammy Butler, Pharm.D. Disclosure Presenter is not affiliated with any manufacturers of the mentioned products or devices in this presentation. Objectives Learning Objectives (Pharmacist): Elizabeth Ekpo Cutter MDMigraine as defined by the International Classification of Headache Disorders third edition ICHD-3 should include the following1At least 5 or more attacks in lifetime2Headache Director, WVU Headache Center. EPIDEMIOLOGY . AND IMPACT. Resolving barriers to care requires several interventions. Migraine is . a common, often disabling disease of the nervous system. . The burden of migraine is greatest for the most severely affected . Primary . Care Professionals . on the Front Line. Supported by an educational grant . from Allergan. In Collaboration . With. Provided by. Kentucky Academy of Family Physicians. September . 25, . 2020. days: -2.9 . in the closure group . vs. -1.7 . in the medical therapy group (p = . 0.17). Mean . reduction in migraine with aura . days: -2.4 . in the closure group . vs. -0.6 . in the medical therapy group (p = 0.01. AMPP=American Migraine Prevalence and Prevention; COPD=chronic obstructive pulmonary disease; MHD=monthly headache day. 1. Buse et al. Headache 2020;60(10):2340–2356. Prevalence of various comorbidities among people with migraine based on headache frequency . An electronic diary study followed 62 people with migraine over 3 months. 1. The most the frequent trigger factors on headache days were . stress. , . fatigue. , and . sleep deprivation. 1. Headaches with trigger factors were more severe than those without trigger factors. 1. Turner et al. Headache 2019;59(4):495–508; 2. . Wöber. et al. J Headache Pain 2006;7(4):188–195; 3. . Pavlovic et al. Headache 2014;54(10):1670–1679; 4. . Sarchielli. . J Headache Pain 2006;7:172–173; .